SCHEMBL4433115

SCHEMBL4433115

C=CCOC(=O)c1ccc(Br)cc1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SNCA P37840 1/20 0.58
CYP3A4 P08684 1/20 0.55
HPGD P15428 3/20 0.51
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
KDM4E B2RXH2 4/20 0.49
LMNA P02545 1/20 0.49
ALDH1A1 P00352 3/20 0.47
TSHR P16473 1/20 0.47
HSD17B10 Q99714 1/20 0.47
MAPT P10636 3/20 0.46
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.44
POLB P06746 1/20 0.44
CES2 O00748 1/20 0.43
CES1 P23141 1/20 0.43
GSK3B P49841 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benzene SCHEMBL27370347 0.96 HPGD (0.57) SNCACYP3A4HPGDNPC1RAB9A
SCHEMBL9063776 0.95 SNCA (0.54) SNCACYP3A4HPGDNPC1RAB9A
SCHEMBL175786 0.90 SNCA (0.67) SNCACYP3A4HPGDKDM4ELMNA
SCHEMBL17386391 0.85 SNCA (0.61) SNCACYP3A4HPGDKDM4ELMNA
SCHEMBL461801 0.85 SNCA (0.61) SNCACYP3A4KDM4ELMNAALDH1A1
SCHEMBL17775085 0.84 SNCA (0.56) SNCACYP3A4NPC1RAB9ALMNA
SCHEMBL175787 0.83 SNCA (0.59) SNCACYP3A4ALDH1A1TSHRHSD17B10
SCHEMBL31182 0.83 SNCA (0.59) SNCACYP3A4HPGDNPC1RAB9A
SCHEMBL5675836 0.83 SNCA (0.59) SNCACYP3A4HPGDKDM4ELMNA
SCHEMBL7090148 0.83 HPGD (0.53) HPGDNPC1RAB9AKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2004611-A1 PROCESS FOR PREPARING RETINOID COMPOUNDS F. Hoffmann-La Roche AG (CH) 2008-12-24 EP claimed
WO-2007113122-A1 PROCESS FOR PREPARING RETINOID COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2007-10-11 WO claimed
US-20070232810-A1 Process for preparing retinoid compounds ROCHE PALO ALTO LLC 2007-10-04 US claimed
EP-1791824-A1 RADICALLY POLYMERIZABLE SULFUR-CONTAINING COMPOUND AND RADICALLY POLYMERIZABLE SULFUR-CONTAINING POLYMER Showa Denko K.K. (JP) 2007-06-06 EP claimed
WO-2006033438-A1 RADICALLY POLYMERIZABLE SULFUR-CONTAINING COMPOUND AND RADICALLY POLYMERIZABLE SULFUR-CONTAINING POLYMER SHOWA DENKO K.K. (JP) 2006-03-30 WO claimed
US-20250296915-A1 NOVEL AMINO ACID DERIVATIVES PEPTIDREAM INC (JP) 2025-09-25 US disclosed
US-20230257343-A1 NOVEL AMINO ACID DERIVATIVES PEPTIDREAM INC (JP) 2023-08-17 US disclosed
EP-4146634-A1 SYNTHESIS OF VINYL CYCLOBUTYL INTERMEDIATES Amgen Inc. (US) 2023-03-15 EP disclosed
CN-113165257-A Apparatus for producing cured resin film and method for producing cured resin film 昭和电工株式会社 2021-07-23 CN disclosed
US-20190202813-A1 Process for preparing 4-(4-(4-(((3R,5R)-5-((1H-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluoro-phenyl)tetrahydrofuran-3-yl)methoxy)-3-methylphenyl)piperazin-1-yl)-N-((1S,2S)-2-hydroxycyclohexyl)benzamide or a pharmaceutically acceptable salt thereof PULMOCIDE LIMITED (GB) 2019-07-04 US disclosed
US-10280155-B2 Process for preparing 4-(4-(4-(((3R,5R)-5-((1H-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluoro-phenyl)tetrahydrofuran-3-yl)methoxy)-3-methylphenyl)piperazin-1-yl)-N-((1S,2S)-2-hydroxycyclohexyl) benzamide or a pharmaceutically acceptable salt thereof PULMOCIDE LIMITED (GB) 2019-05-07 US disclosed
US-20180251453-A1 COMPOUNDS PULMOCIDE LIMITED (GB) 2018-09-06 US disclosed
WO-2007086607-A2 RADICALLY POLYMERIZABLE COMPOUND HAVING A CYCLIC DITHIOCARBONATE GROUP SHOWA DENKO K.K. (JP) 2007-08-02 WO disclosed
EP-1791824-A1 RADICALLY POLYMERIZABLE SULFUR-CONTAINING COMPOUND AND RADICALLY POLYMERIZABLE SULFUR-CONTAINING POLYMER Showa Denko K.K. (JP) 2007-06-06 EP disclosed
WO-2006033438-A1 RADICALLY POLYMERIZABLE SULFUR-CONTAINING COMPOUND AND RADICALLY POLYMERIZABLE SULFUR-CONTAINING POLYMER SHOWA DENKO K.K. (JP) 2006-03-30 WO disclosed
CN-1466598-A Plastic lens composition, plastic lens and method for producing the plastic lens �Ѻ͵繤��ʽ���� 2004-01-07 CN disclosed
WO-2003010566-A2 PLASTIC LENS MATERIAL, PLASTIC LENS COMPOSITION, PLASTIC LENS OBTAINED BY CURING THE COMPOSITION AND PROCESS FOR PRODUCING THE PLASTIC LENS SHOWA DENKO K. K. (JP) 2003-02-06 WO disclosed
US-6319948-B2 PREVENTION AND/OR MINIMIZATION OF SURGICAL ADHESION FORMATION BY ADMINISTERING CERTAIN SUBSTITUTED (5,6)-DIHYDRONAPHTHALENYL COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY 2001-11-20 US disclosed
US-20010003780-A1 Retinoid antagonists and uses thereof TRAMPOSCH KENNETH M (US) 2001-06-14 US disclosed
WO-1998046228-A1 RETINOID ANTAGONISTS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY (US) 1998-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10280155-B2 Process for preparing 4-(4-(4-(((3R,5R)-5-((1H-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluoro-phenyl)tetrahydrofuran-3-yl)methoxy)-3-methylphenyl)piperazin-1-yl)-N-((1S,2S)-2-hydroxycyclohexyl) benzamide or a pharmaceutically acceptable salt thereof HRH4, HRH1, CYP2S1 SNCA 793/4885CYP3A4 13/4885HPGD 1540/4885
US-20250296915-A1 NOVEL AMINO ACID DERIVATIVES DNPEP, BCAT1, ANPEP SNCA 2855/4885CYP3A4 4395/4885HPGD 3826/4885
US-20010003780-A1 Retinoid antagonists and uses thereof RARA, RARB, RARG SNCA 4557/4885CYP3A4 3104/4885HPGD 318/4885
US-20230257343-A1 NOVEL AMINO ACID DERIVATIVES DNPEP, BCAT1, ANPEP SNCA 2070/4885CYP3A4 4397/4885HPGD 2952/4885
US-20190202813-A1 Process for preparing 4-(4-(4-(((3R,5R)-5-((1H-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluoro-phenyl)tetrahydrofuran-3-yl)methoxy)-3-methylphenyl)piperazin-1-yl)-N-((1S,2S)-2-hydroxycyclohexyl)benzamide or a pharmaceutically acceptable salt thereof HRH4, HRH1, CYP2S1 SNCA 793/4885CYP3A4 13/4885HPGD 1540/4885
US-20180251453-A1 COMPOUNDS MYC, DPM1, ERG28 SNCA 3302/4885CYP3A4 212/4885HPGD 1465/4885
US-20070232810-A1 Process for preparing retinoid compounds RARB, RARG, RARA SNCA 4568/4885CYP3A4 252/4885HPGD 658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.